Hans Informatic – AI Medical Diagnosis Assistant

Medical AI Dashboard

Real-time patient analytics & diagnostic intelligence

📋

1,247

Total Reports Analyzed

▲ 12.4% this month

✅

94.6%

AI Accuracy Rate

▲ 2.1% improvement

⚠️

38

High Risk Patients

▼ 5 from last week

🚨

7

Critical Alerts

▼ 2 resolved today

📈 Reports Analyzed Over Time

🩺 Disease Distribution

⚡ Risk Level Distribution

🔬 Report Types

📊 Accuracy by Category

🚨 Recent Critical Findings

Patient ID	Report Type	Finding	Risk Level	AI Confidence	Date
#PT-4821	Blood Panel	Elevated Troponin (2.4 ng/mL)	🔴 Critical	97.2%	2025-01-15
#PT-3907	MRI Brain	Suspected Lesion – Parietal Lobe	🟠 High	91.4%	2025-01-15
#PT-5102	Lipid Panel	LDL 198 mg/dL – Hyperlipidemia	🟡 Medium	88.7%	2025-01-14
#PT-2214	HbA1c	HbA1c 9.1% – Poor Glycemic Control	🟠 High	96.1%	2025-01-14
#PT-6634	CT Chest	Pulmonary Nodule 8mm – Follow Up	🟡 Medium	84.3%	2025-01-13
#PT-1892	CBC	WBC 14,200 – Possible Infection	🟡 Medium	89.5%	2025-01-13

Upload & Analyze

Support for all medical document formats — AI-powered extraction

📤 Document Upload

🏥

Drop Medical Documents Here

Click to browse or drag & drop any format

PDF JPG/PNG TIFF DICOM ZIP DOCX Handwritten HEIC

⚙️ Analysis Options

Disease Prediction & Risk Assessment Extract & Tabulate All Values Generate Visual Analytics Doctor Recommendations Compare with Previous Reports Drug Interaction Check

🤖 AI Analysis Results

🏥

Upload a medical document to begin AI analysis

Supports handwritten reports, PDFs, scans & images

🩸 Complete Blood Count Analysis

AI-powered hematological analysis with trend tracking

14.2g/dL

Hemoglobin

✓ Normal

4.8M/μL

RBC Count

✓ Normal

14.2K/μL

WBC Count

⚠ High

285K/μL

Platelets

✓ Normal

42%

Hematocrit

✓ Normal

88fL

MCV

✓ Normal

📊 CBC Trend (6 Months)

🔬 WBC Differential

📋 Complete CBC Values

Test	Result	Unit	Normal Range	Status	Notes
Hemoglobin (Hgb)	14.2	g/dL	13.5–17.5 (M) / 12–15.5 (F)	Normal	Within range
Hematocrit (Hct)	42	%	41–53% (M) / 36–46% (F)	Normal	Within range
RBC Count	4.8	M/μL	4.5–5.9 (M) / 4.1–5.1 (F)	Normal	Within range
WBC Count	14,200	K/μL	4,500–11,000	⚠ High	Possible infection/inflammation
Platelet Count	285	K/μL	150,000–400,000	Normal	Within range
MCV	88	fL	80–100	Normal	Normocytic
MCH	29.4	pg	27–33	Normal	Within range
MCHC	33.5	g/dL	32–36	Normal	Within range
Neutrophils	78	%	50–70%	⚠ High	Suggests bacterial infection
Lymphocytes	16	%	20–40%	⚠ Low	Relative lymphopenia
Monocytes	4	%	2–8%	Normal	Within range
Eosinophils	2	%	1–4%	Normal	Within range

🤖 AI Interpretation

Analyzed: Jan 15, 2025 09:42 AM

🚨

Leukocytosis DetectedWBC count of 14,200/μL with neutrophilia (78%) strongly suggests an active bacterial infection or inflammatory process. Immediate evaluation recommended.

⚠️

Relative LymphopeniaLymphocytes at 16% (low) correlates with the elevated neutrophil count, consistent with acute bacterial infection pattern.

✅

Red Cell Indices NormalHemoglobin, hematocrit, MCV, MCH, MCHC all within normal limits. No evidence of anemia or hemolytic disorder.

👨‍⚕️ Recommended Actions:

1. Order blood culture to identify causative organism
2. CRP and ESR to quantify inflammation
3. Urine analysis to rule out UTI
4. Chest X-ray if respiratory symptoms present
5. Refer to Infectious Disease specialist if no improvement in 48h

💊 Lipid Panel Analysis

Cardiovascular risk stratification & cholesterol management

⬆️

242

Total Cholesterol (mg/dL)

⚠ High (>200)

🔴

168

LDL Cholesterol (mg/dL)

⚠ Very High (>160)

🟢

52

HDL Cholesterol (mg/dL)

✓ Acceptable (>40)

📊

186

Triglycerides (mg/dL)

⚠ Borderline High

📈 Lipid Trend (12 Months)

🎯 Cardiovascular Risk Score

68%

10-Year Cardiovascular Risk

🟠 High Risk

📋 Lipid Values Detail

Marker	Value	Unit	Optimal	Borderline	High	Status
Total Cholesterol	242	mg/dL	<200	200–239	≥240	High
LDL Cholesterol	168	mg/dL	<100	130–159	≥160	Very High
HDL Cholesterol	52	mg/dL	≥60	40–59	<40	Borderline
Triglycerides	186	mg/dL	<150	150–199	≥200	Borderline
VLDL Cholesterol	37	mg/dL	<30	30–40	≥40	Borderline
Non-HDL Cholesterol	190	mg/dL	<130	—	≥160	High
LDL/HDL Ratio	3.23	ratio	<2.0	2.0–3.0	>3.0	High

🍬 Glucose & HbA1c Analysis

Diabetes screening, glycemic control & insulin resistance assessment

🍬

9.1%

HbA1c

Poor Control (≥8%)

📊

182

Fasting Glucose (mg/dL)

⚠ Diabetic Range

⏱️

248

Post-Prandial Glucose

⚠ Very High

💉

18.2

Insulin (μIU/mL)

⚠ Resistance

📈 Glucose Trend (90 Days)

🎯 HbA1c History

📋 Diabetes Panel

Test	Value	Unit	Normal	Pre-Diabetic	Diabetic	Status
HbA1c	9.1	%	<5.7%	5.7–6.4%	≥6.5%	Diabetic
Fasting Blood Glucose	182	mg/dL	70–99	100–125	≥126	Diabetic
2-hr Post-Prandial	248	mg/dL	<140	140–199	≥200	Diabetic
Fasting Insulin	18.2	μIU/mL	2–10	10–20	>20	Borderline
HOMA-IR	8.2	index	<2.0	2.0–3.0	>3.0	Insulin Resistant
C-Peptide	2.4	ng/mL	0.8–3.1	—	—	Normal

🫀 Liver Function Test (LFT)

Hepatic panel analysis with fibrosis risk assessment

⬆️

82

ALT (U/L)

⚠ Elevated (Nl: 7-56)

⬆️

65

AST (U/L)

⚠ Borderline

✅

3.8

Albumin (g/dL)

✓ Normal

📋 Liver Function Panel

Test	Value	Unit	Reference Range	Status
ALT (SGPT)	82	U/L	7–56	High
AST (SGOT)	65	U/L	10–40	Elevated
ALP	120	U/L	44–147	Normal
Total Bilirubin	1.4	mg/dL	0.2–1.2	Borderline
Direct Bilirubin	0.3	mg/dL	0–0.3	Normal
Albumin	3.8	g/dL	3.5–5.0	Normal
Total Protein	7.2	g/dL	6.3–8.2	Normal
GGT	78	U/L	9–48	Elevated
PT/INR	1.1	ratio	0.9–1.1	Normal

🫁 Kidney Function Test (KFT)

Renal panel, GFR estimation & CKD staging

🔵

1.2

Creatinine (mg/dL)

✓ Normal

💧

72

eGFR (mL/min)

CKD Stage 2

🧂

18

BUN (mg/dL)

✓ Normal

⬆️

42

Uric Acid (mg/dL)

⚠ Borderline

📋 Renal Function Panel

Test	Value	Unit	Reference	Status	CKD Stage Implication
Serum Creatinine	1.2	mg/dL	0.7–1.3 (M)	Normal	—
eGFR	72	mL/min/1.73m²	≥90	Mildly Reduced	CKD Stage 2
BUN	18	mg/dL	7–25	Normal	—
BUN/Creatinine Ratio	15.0	ratio	10–20	Normal	—
Uric Acid	8.1	mg/dL	3.4–7.0 (M)	High	Gout risk
Sodium	139	mEq/L	136–145	Normal	—
Potassium	4.1	mEq/L	3.5–5.0	Normal	—
Urine Protein (24h)	320	mg/day	<150	Microalbuminuria	Monitor closely

⚡ Thyroid Panel Analysis

Thyroid function, autoimmunity & hormone assessment

⬆️

8.4

TSH (mIU/L)

⚠ Hypothyroid (Nl: 0.4–4.0)

⬇️

0.8

Free T4 (ng/dL)

⚠ Low Normal

✅

3.1

Free T3 (pg/mL)

✓ Normal

📋 Thyroid Panel

Test	Value	Unit	Reference	Status	Interpretation
TSH	8.4	mIU/L	0.4–4.0	High	Primary Hypothyroidism
Free T4 (FT4)	0.8	ng/dL	0.9–1.7	Low	Confirms hypothyroidism
Free T3 (FT3)	3.1	pg/mL	2.3–4.1	Normal	Within range
Total T4	6.4	μg/dL	5.1–12.0	Normal	Within range
Anti-TPO Antibodies	420	IU/mL	<35	Very High	Hashimoto's Thyroiditis
Anti-Thyroglobulin	180	IU/mL	<115	High	Autoimmune pattern

🧠 MRI Brain Analysis

AI-powered neuroimaging interpretation & anomaly detection

🧠 MRI Viewer (Simulation)

              T1-Weighted Axial • TR:500ms TE:15ms • 3T MRI
            

🔍 AI Findings

🚨

Suspected Lesion – Right ParietalHyperintense area ~8mm, possible early-stage glioma. Immediate neurology referral.

⚠️

White Matter ChangesScattered periventricular FLAIR hyperintensities consistent with small vessel disease.

✅

Ventricular SystemNormal size and configuration. No midline shift detected.

✅

Posterior FossaCerebellum and brainstem unremarkable. No mass effect.

AI Confidence Score

91.4%

📋 MRI Report Summary

Region	Finding	Size	Signal	Risk	Recommendation
Right Parietal Lobe	Hyperintense nodule	8mm	T1 Iso / T2 Hyper	High	Biopsy/MRS recommended
Periventricular WM	FLAIR hyperintensities	Multiple	FLAIR Hyper	Medium	Follow-up in 6 months
Corpus Callosum	No abnormality	—	Normal	Normal	—
Basal Ganglia	No abnormality	—	Normal	Normal	—
Cerebellum	No abnormality	—	Normal	Normal	—
Brainstem	No abnormality	—	Normal	Normal	—

🫁 CT Scan Analysis

Thoracic & abdominal CT with AI nodule detection

🫁 Pulmonary Findings

⚠️

Pulmonary Nodule – RLL8mm solid nodule in right lower lobe. Fleischner criteria: Annual CT follow-up recommended.

✅

Lung ParenchymaNo consolidation, pleural effusion, or pneumothorax identified.

✅

MediastinumNo lymphadenopathy. Heart size normal. Aortic caliber normal.

📊 Nodule Size Tracking

📋 CT Scan Report

Location	Density	Size (mm)	Attenuation	Finding	Risk	Follow-up
RLL Nodule	Solid	8	-10 HU	Indeterminate nodule	Medium	CT in 12 months
LUL Apex	Ground glass	4	-600 HU	Sub-solid opacity	Low	CT in 2 years
Mediastinum	—	—	—	No adenopathy	Normal	Routine
Pleura	—	—	—	No effusion	Normal	—
Liver (incidental)	Cystic	12	8 HU	Simple hepatic cyst	Benign	No follow-up

🦴 X-Ray Analysis

Chest & skeletal radiograph AI interpretation

❤️

0.48

Cardiothoracic Ratio

✓ Normal

🫁

Normal

Lung Fields

No consolidation

🦴

Intact

Skeletal Survey

No fractures

📋 X-Ray Findings

Structure	Finding	Severity	Recommendation
Heart	Normal size, CTR 0.48	Normal	Routine screening
Lungs	Clear, no consolidation/effusion	Normal	—
Bony Thorax	No fractures, normal density	Normal	—
Diaphragm	Normal cupola bilaterally	Normal	—
Mediastinum	Slight widening – mediastinal fat	Borderline	CT if clinical concern
Costophrenic Angles	Sharp bilaterally	Normal	—

❤️ Cardiac Risk Assessment

Multi-marker cardiovascular risk stratification

🚨

2.4

Troponin I (ng/mL)

⚠ Critical (Nl: <0.04)

⬆️

8.2

hsCRP (mg/L)

⚠ High Risk

💜

284

BNP (pg/mL)

⚠ Elevated

🔵

12.4

CK-MB (ng/mL)

⚠ High

❤️ Cardiac Biomarker Trend

🎯 10-Year CVD Risk (Framingham)

68%

Framingham Risk Score

10-year Risk68%

📋 Cardiac Panel

Biomarker	Value	Unit	Normal	Status	Clinical Significance
Troponin I (hsTnI)	2.4	ng/mL	<0.04	Critical	Myocardial injury – rule out MI
CK-MB	12.4	ng/mL	<5.0	High	Myocardial necrosis marker
BNP	284	pg/mL	<100	Elevated	Suggests cardiac stress/HF
hsCRP	8.2	mg/L	<1.0	High	Significant CV inflammation
D-Dimer	0.42	μg/mL	<0.5	Normal	PE unlikely
Fibrinogen	480	mg/dL	200–400	Elevated	Thrombotic risk

💉 Diabetes Risk Profiling

Comprehensive metabolic syndrome & diabetes risk analysis

📊 Metabolic Risk Radar

🎯 Diabetes Risk Factors

HbA1c9.1% — Diabetic

Fasting Glucose182 mg/dL

BMI29.4 (Overweight)

Insulin Resistance (HOMA-IR)8.2

Physical ActivityModerate

🔬 Cancer Tumor Markers

Multi-panel tumor marker analysis & early detection

🔴

8.4

PSA (ng/mL)

⚠ High (Nl: <4.0)

✅

18

CEA (ng/mL)

✓ Normal

✅

22

CA 19-9 (U/mL)

✓ Normal

🔵

12

AFP (ng/mL)

✓ Normal

📋 Tumor Marker Panel

Marker	Value	Unit	Reference	Status	Cancer Association	Action
PSA (Total)	8.4	ng/mL	<4.0	High	Prostate cancer / BPH	Urology referral
Free PSA Ratio	14%	%	>25%	Low	Prostate cancer risk ↑	Biopsy consider
CEA	2.4	ng/mL	<5.0 (NS)	Normal	Colorectal, lung	Routine
CA 125	22	U/mL	<35	Normal	Ovarian cancer	Routine
CA 15-3	18	U/mL	<30	Normal	Breast cancer	Routine
CA 19-9	22	U/mL	<37	Normal	Pancreatic, GI	Routine
AFP	12	ng/mL	<20	Normal	Hepatocellular, testicular	Routine
Beta-HCG	0.3	mIU/mL	<5	Normal	Testicular, gestational	Routine

💊 Medication Tracker

Current medications, dosing, interactions & recommendations

💊

Metformin HCl

Biguanide antidiabetic • Decreases hepatic glucose production

⚠ Monitor: Renal function, Vitamin B12

1000mg

Twice daily

❤️

Atorvastatin

HMG-CoA reductase inhibitor • Lipid-lowering agent

⚠ Monitor: Liver enzymes, myopathy signs

40mg

Once daily (PM)

💧

Ramipril (ACE Inhibitor)

Angiotensin-converting enzyme inhibitor • Blood pressure control

⚠ Monitor: K+ levels, renal function, cough

5mg

Once daily (AM)

🔵

Levothyroxine (T4)

Thyroid hormone replacement • Hypothyroidism management

✓ Take 30 min before breakfast, avoid antacids

75mcg

Once daily (AM)

🩸

Aspirin (Low-dose)

Antiplatelet agent • Cardiovascular risk reduction

⚠ Monitor: GI bleeding, renal function

75mg

Once daily (after food)

📋 Patient Medical History

Longitudinal health record & clinical timeline

🕐 Clinical Timeline

Jan 15, 2025

Elevated Cardiac Biomarkers

Troponin I 2.4 ng/mL – Cardiology consultation initiated

Dec 2024

HbA1c 9.1% – Poor Control

Metformin dose increased to 1000mg BID. Dietitian referral made.

Oct 2024

MRI Brain – Parietal Lesion

8mm hyperintense lesion identified. Neurology referral pending biopsy.

Aug 2024

Hypothyroidism Diagnosed

Anti-TPO 420 IU/mL – Hashimoto's thyroiditis. Levothyroxine started.

Jun 2024

Hyperlipidemia Managed

LDL 168 mg/dL – Atorvastatin 40mg initiated, lifestyle counseling.

Mar 2024

Type 2 Diabetes Confirmed

Fasting glucose 182 mg/dL. Started on Metformin therapy.

👤 Patient Profile

NameJohn D. (PT-4821)

Age / Gender58 yrs / Male

Blood GroupB+

BMI29.4 (Overweight)

AllergiesPenicillin, Sulfa

Primary PhysicianDr. Sarah Ahmed

🏥 Active Diagnoses

🔴 Type 2 Diabetes Mellitus (E11)

🔴 Acute Cardiac Event (I21.9)

🟡 Hashimoto's Thyroiditis (E06.3)

🟡 Hyperlipidemia (E78.5)

🟢 CKD Stage 2 (N18.2)

📊 All Reports

Complete medical report archive with search & filter

#	Report ID	Patient	Type	Key Finding	Risk	AI Confidence	Date	Status
1	RPT-001	PT-4821	Cardiac Panel	Troponin 2.4 ng/mL	Critical	97.2%	2025-01-15	Under Review
2	RPT-002	PT-3907	MRI Brain	Parietal lesion 8mm	High	91.4%	2025-01-15	Pending
3	RPT-003	PT-5102	Lipid Panel	LDL 168, TC 242	High	96.8%	2025-01-14	Complete
4	RPT-004	PT-2214	HbA1c/Glucose	HbA1c 9.1%	High	98.1%	2025-01-14	Complete
5	RPT-005	PT-6634	CT Chest	Pulmonary nodule 8mm	Medium	84.3%	2025-01-13	Complete
6	RPT-006	PT-1892	CBC	WBC 14,200 – Leukocytosis	Medium	89.5%	2025-01-13	Complete
7	RPT-007	PT-7741	LFT	ALT 82, GGT 78	Medium	92.1%	2025-01-12	Complete
8	RPT-008	PT-3382	Thyroid	TSH 8.4, Anti-TPO 420	High	95.7%	2025-01-12	Complete
9	RPT-009	PT-9012	KFT	eGFR 72, Microalbuminuria	Medium	87.9%	2025-01-11	Complete
10	RPT-010	PT-4401	Cancer Markers	PSA 8.4 ng/mL	High	93.2%	2025-01-11	Pending